# Original Article Transanal hemorrhoidal dearterialization versus stapled hemorrhoidectomy in the treatment of hemorrhoids: an update meta-analysis of randomized control trials

Qi Yao<sup>1\*</sup>, Honglei Chen<sup>2\*</sup>, Xingyang Wan<sup>3</sup>, Lanzhen He<sup>3</sup>, Yanan Liu<sup>2</sup>

<sup>1</sup>Department of Colonproctology Surgery, Shenzhen People's Hospital, Shenzhen, China; <sup>2</sup>Department of Gastrointestinal Endoscopy, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangdong, China; <sup>3</sup>Department of Colonproctology Surgery, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangdong, China. \*Co-first authors.

Received September 13, 2017; Accepted September 5, 2018; Epub November 15, 2018; Published November 30, 2018

**Abstract:** This study aims to compare the clinical outcomes of stapled hemorrhoidectomy (SH) and transanal hemorrhoidal dearterialization (THD) for the treatment of hemorrhoids diseases by a meta-analysis. Randomized control trials (RCTs), published between January 1, 1996 and June 31, 2017, comparing SH with THD were searched in databases, including MEDLINE, PubMed, Web of science, EMbase and the Cochrane Library database were. Seven RCTs, including 877 patients, were included in this meta-analysis. No statistically significant differences were noted between SH and THD in terms of complications (OR, 1.02; 95% CI, 0.75, 1.38), residual prolapse (OR, 0.61; 95% CI, 0.28, 1.35), urinary retention rate (OR, 1.25; 95% CI, 0.66, 2.34), and satisfaction rate (OR, 1.08; 95% CI, 0.34, 3.41). The bleeding rate and total recurrence rate was higher in THD than in SH. The present study showed that no significant difference between SH and THD in terms of postoperative pain (OR, 0.43; 95% CI, 0.43, 1.29), operative time (OR, -2.54; 95% CI, -6.85, 1.76), hospital time (OR, -0.00; 95% CI, -0.21, 0.20), time before returning to work (OR, 1.21; 95% CI, -1.35, 3.77), and reoperation rate (OR, 1.81; 95% CI, 0.93, 3.54). In conclusion, both procedures are simple and easy to perform for the treatment of hemorrhoids. However, THD leading to a higher rate of bleeding and recurrence rate in the treatment of hemorrhoids. Future studies addressing with a long follow-up period are needed to validate these results.

Keywords: Meta analysis, hemorrhoids, stapled hemorrhoidectomy, transanal hemorrhoidal dearterialization

### Introduction

Hemorrhoids is a common benign anorectal disease diagnosed at the proctology clinic [1]. Conventional hemorrhoidectomy (CH) is the main surgical treatment for hemorrhoids [2]. However, CH is associated with a number of complications, such as bleeding, pain, residual prolapse, urinary retention anal stenosis and anal incontinence. Therefore, a more effective method is needed for the treatment of hemorrhoidal diseases [3].

Morinaga et al first introduced a new technique named transanal hemorrhoidal dearterialization (THD) or hemorrhoidal artery ligation (HAL) in 1995 [4]. Compared with CH, the advantages of THD such as limited postoperative pain, shorter operative time and quicker return to work were confirmed by several trials [5]. Longo et al. introduced another new technique named stapler hemorrhoidectomy (SH), also known as procedure for prolapse and hemorrhoids (PPH), in 1998 [6]. Although some postoperative complications have been reported, SH is a fast procedure characterized by less postoperative pain, short hospital stay and earlier return to work [7, 8].

Several randomized controlled trials compared SH with THD have been published. A meta-analysis compared THD with SH was published in 2012. Only three randomized controlled trials encompassing 150 patients were included, and one of the trials was published as abstract. In 2015, a network meta-analysis indicated that

Trial	Year	Country	Туре	Patients, n (M/F)	Mean age, years	Grade of hemorrhoids	Follow-up time (month)	QS
Festen et al. [10]	2009	Netherlands	SH	18 (13/5)	35	2 and 3	26 (20-30)	2
			TDH	23 (16/7)	39			
Khafagy et al. [11]	2009	Egypt	SH	15 (9/6)	40.1±11.2	3 and 4	3	2
			TDH	15 (13/20)	40.1±9.8			
Giordano et al. [12]	2011	UK	SH	24 (16/8)	48 (35-78)	2 and 3	36	2
			TDH	28 (20/8)	54 (23-73)			
Infantino et al. [13]	2012	Italy	SH	84 (58/26)	47.6±11.9	3 and 4	35 (27-43)	3
			TDH	85 (58/27)	46.2±11.5			
Verre et al. [14]	2013	Italy	SH	63 (24/39)	47.8	3 and 4	24	2
			TDH	59 (22/37)	48.9			
Paul et al. [15]	2016	France	SH	196 (126/70)	50±11.7	2, 3 and 4	12	3
			TDH	197 (121/76)	50.5±12.6			
Venturi et al. [16]	2016	Italy	SH	35 (17/18)	50.2±4.4	3 and 4	36	3
			TDH	35 (18/17)	49.5±5.3			

Table 1. Patients characteristics and methodological quality scores

QS: quality scores.

THD and SH were associated with less postoperative pain and earlier return to work, but a higher recurrence rates. However, which kind of technique is better is still in controversy. Since then, two further RCTs with a large number of patients have reported inconsistent results. In order to provide the latest and more solid evidence and minimize potential bias caused by limited publications, we performed an updated meta-analysis to further consolidate the effect of THD and SH in the treatment of hemorrhoids.

### Material and methods

### Data sources

Relevant prospective RCTs that compared SH with THD were included in this meta-analysis. Randomizes control trials (RCTs) compared SH with THD were searched from the databases including MEDLINE, PubMed, Web of science, Embase and Cochrane Library database from 1996 to June 31, 2017, using the following search terms: "hemorrhoids", "hemorrhoidal disease" and "prolapsing hemorrhoids" in combination with "procedure for residual prolapse and hemorrhoids", "stapled hemorrhoidopexy", "hemorrhoidal artery ligation", "transanal hemorrhoidal de-arterialisation", and "surgical treatment" combinded with "randomized trials". Additional publications were searched in the references list of the included trials. Two observers identified and extracted the date from each study independently and blindly.

### Inclusion and exclusion criteria

Studied were included follow the criteria: RCTs compared THD with SH, published as a full article in English. Trials without data for retrieval, abstracts, retrospective trials, duplicate publications, and unpublished trials were excluded.

### Statistical analysis

The RevMan5.2 software (The Cochrane Collaboration, Oxford, UK) was used for the meta-analysis. For all dichotomous variables, the odds ratio (OR) with 95% confidence interval (CI) was calculated. For continuous variables, weighted mean difference (WMD) was calculated with 95% confidence interval. The standard deviation was calculated following to the guidelines of the handbook Cochrane Collaboration. If mean values were not available for continuous outcomes, median values were used according to the guidelines of the Cochrane Collaboration. The fixed effects model and the random effects model were calculated to analyze the overall effect of the combined outcomes. Chi-Square statistic, with significance set at P<0.05, was used to explore the heterogeneity among the trials. Only the results of random effects model were reported in case of heterogeneity. We use the forest plot to show the results of the meta-analysis.



trials ( $\chi^2$ =4.76, df=6, *P*= 0.58; l<sup>2</sup>=0%). In the fixed models, no significant difference was noted in the bleeding rate compared THD with SH (OR, 1.67; 95% Cl, 0.96, 2.89; Z=1.83; P=0.07; Figure 2B).

Residual prolapse: Data from four trials suggested that no heterogeneity was noted among trials in terms of residual prolapse ( $\chi^{2=}$ 1.41, df=3, P=0.70; I<sup>2</sup>=0%). In the fixed models, no significant difference was noted in the residual prolapse compared THD with SH (OR, 0.61; 95% CI, 0.28, 1.35; Z=1.22; P=0.22; Figure 2C).

Urinary retention: Regarding urinary retention, no heterogeneity was observ-

### Methodological quality assessment

Modified Jadad scale was used to assess the quality of included RCTs [9]. Publication bias was evaluated using funnel plots.

### Results

Seven RCTs on 877 patients were included for the meta-analysis [10-16]. Patients' information extracted from including trials and methodological quality are showed in **Table 1**. **Figure 1** presents the search strategy of this study. Funnel plots showed no publication bias was exist in this meta-analysis.

### Postoperative complications and clinical outcomes

Total complications: No heterogeneity was noted among trials in terms of total complications ( $\chi^2$ =3.24, df=6, *P*=0.78; l<sup>2</sup>=0%). In the fixed models, no significant difference was noted in the total complications rate between SH and THD (OR, 1.02; 95% Cl, 0.75, 1.38; Z=0.11; P=0.91; Figure 2A).

Bleeding: Concerning the major bleeding after operation, no heterogeneity was noted among

ed among trials ( $\chi^2$ =5.37, df=5, *P*=0.37; l<sup>2</sup>=7%). In the fixed models, no statistically significant difference was noted in terms of urinary retention rate compared THD with SH (OR, 1.25; 95% Cl, 0.66, 2.34; Z=0.68; P=0.50; Figure 2D).

Recurrence: Concerning recurrence after hemorrhoidectomy, no statistically significant heterogeneity among trials ( $\chi^2$ =3.63, df=4, P= 0.46, I<sup>2</sup>=0%). In the fixed models, a statistically significant difference was noted in terms of recurrence rate compared THD with SH (OR, 0.51; 95% CI, 0.29, 0.92; Z=2.25; P=0.0.02; Figure 2E). The total recurrence rate was higher in THD group than in SH group. For subgroup analysis, we including the trial with a follow up time less three years but more than one, a significant difference was observed in terms of recurrence rate [10]. However, when we only including the two trials with 3 years follow up, no significant difference was observed compared THD with SH [12, 16].

Satisfaction rate: Only two trials reported the information about the satisfaction rate compared THD with SH. No statistically significant heterogeneity was noted among trials ( $\chi^2$ =1.08, df=1, P=0.30, I<sup>2</sup>=7%), therefore, we used the fixed models. No statistically significant differ-

### A Total complications

	SH		THE	)		Odds Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	M	H. Fixed, 95%	CI	
2009 Khafagy	3	15	2	15	1.9%	1.63 [0.23, 11.46]		-			
2009 Festen	7	18	6	23	3.9%	1.80 [0.48, 6.81]				_	
2011 Giordano	6	24	4	28	3.3%	2.00 [0.49, 8.15]					
2012 Infantino	27	84	26	85	21.0%	1.07 [0.56, 2.06]					
2013 Verre	9	63	8	59	8.5%	1.06 [0.38, 2.97]			<u> </u>		
2016 Paul	64	196	68	197	54.8%	0.92 [0.61, 1.40]					
2016 Venturi	3	35	6	35	6.6%	0.45 [0.10, 1.98]					
Total (95% CI)		435		442	100.0%	1.02 [0.75, 1.38]			•		
Total events	119		120								
Heterogeneity: Chi <sup>2</sup> = 3	3.24, df =	6 (P = 0	0.78); I² =	0%						10	
Test for overall effect:	Z = 0.11 (	P = 0.9	1)				0.01	0.1	SH THD	10	100

### B Bleeding

	SH THD				Odds Ratio	Odds Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		М-Н,	Fixed, 95%	CI	
2009 Khafagy	1	15	0	15	2.3%	3.21 [0.12, 85.20]			<u> </u>		
2009 Festen	2	18	1	23	3.9%	2.75 [0.23, 33.01]			<u> </u>		_
2011 Giordano	2	24	0	28	2.1%	6.33 [0.29, 138.67]		_		•	$\longrightarrow$
2012 Infantino	3	84	5	85	23.8%	0.59 [0.14, 2.56]					
2013 Verre	5	63	0	59	2.3%	11.19 [0.60, 206.92]			+		$\longrightarrow$
2016 Paul	12	196	8	197	37.2%	1.54 [0.62, 3.86]			-+=		
2016 Venturi	27	35	25	35	28.4%	1.35 [0.46, 3.96]					
Total (95% CI)		435		442	100.0%	1.67 [0.96, 2.89]			•		
Total events	52		39								
Heterogeneity: Chi <sup>2</sup> = 4	1.76, df =	6 (P = 0	0.58); l² =	0%					_ <u> </u>		
Test for overall effect: 2	Z = 1.83 (	P = 0.0	7)				0.01	0.1	SH THD	10	100

### C Residual prolapse

	. SH		THE	)		Odds Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	М	-H, Fixed, 95%		
2009 Khafagy	5	18	6	23	23.5%	1.09 [0.27, 4.37]					
2009 Festen	2	15	5	15	26.8%	0.31 [0.05, 1.93]					
2011 Giordano	2	24	3	28	15.7%	0.76 [0.12, 4.96]				-	
2016 Venturi	3	35	6	35	33.9%	0.45 [0.10, 1.98]					
Total (95% CI)		92		101	100.0%	0.61 [0.28, 1.35]					
Total events	12		20								
Heterogeneity: Chi <sup>2</sup> =	1.41, df =	3 (P = 0					100				
Test for overall effect:	Z = 1.22 (	P = 0.2	2)				0.01	0.1	SH THD	10	100

## D Urinary retention

•	SH		THE	)		Odds Ratio			Odds Ratio	)	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	М	-H, Fixed, 95	% CI	
2009 Khafagy	1	15	0	15	2.6%	3.21 [0.12, 85.20]					
2009 Festen	1	18	0	23	2.4%	4.03 [0.15, 104.93]				•	$\rightarrow$
2011 Giordano	0	24	1	28	7.9%	0.37 [0.01, 9.62]					
2012 Infantino	12	84	5	85	24.7%	2.67 [0.90, 7.94]					
2013 Verre	3	63	5	59	28.5%	0.54 [0.12, 2.37]					
2016 Paul	4	196	6	197	34.0%	0.66 [0.18, 2.39]		-			
2016 Venturi	0	35	0	35		Not estimable					
Total (95% CI)		435		442	100.0%	1.25 [0.66, 2.34]			-		
Total events	21		17								
Heterogeneity: Chi <sup>2</sup> =	5.37, df =	5 (P = 0	0.37); l² =	7%				0.1			100
Test for overall effect:	Z = 0.68 (	P = 0.5	0)				0.01	0.1	SH THD		100

### E Recurrence

		SH		THD	)		Odds Ratio	Odds Ratio
	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% Cl
	2009 Festen	5	18	5	23	9.5%	1.38 [0.33, 5.79]	
	2011 Giordano	2	24	3	28	7.6%	0.76 [0.12, 4.96]	
	2012 Infantino	6	84	12	85	33.0%	0.47 [0.17, 1.31]	
	2016 Paul	2	196	10	197	29.5%	0.19 [0.04, 0.89]	<b>e</b>
	2016 Venturi	5	35	8	35	20.5%	0.56 [0.16, 1.93]	
	Total (95% CI)		357		368	100.0%	0.51 [0.29, 0.92]	•
	Total events	20		38				
Heterogeneity: $Chi^2 = 3.63$ , $df = 4$ (P = 0.46); $I^2 = 0\%$								
	Test for overall effect:		-					0.01 0.1 1 10 100 SH THD



Figure 2. Postoperative complications and Clinical outcomes: (A) Total complications (B) Bleeding; (C) Residual prolapse; (D) Urinary retention. (E) Recurrence; (F) Satisfaction rate.

ence was observed regarding the satisfaction rate (OR, 1.08; 95% CI, 0.34, 3.41; Z=0.13; P =0.89; Figure 2F).

### Surgical parameters

Postoperative pain scores: Data from five trials suggested that there was a significant heterogeneity among trials regarding postoperative pain (Tau<sup>2</sup>=0.68,  $\chi^2$ =34.99, ,0001, I<sup>2</sup>=89%). In the random-effects model, no statistically significant difference was noted in the postoperative pain compared THD with SH (OR, 0.43; 95% Cl, -0.43, 1.29; Z=0.97; *P*=0.33; Figure **3A**).

*Operative time:* Data from six trials suggested that a statistically significant heterogeneity was noted among trials regarding operative time (Tau<sup>2</sup>=27.05,  $\chi^2$ =93.07, df=5, *P*<0.00001, l<sup>2</sup>= 95%). In the random-effects model, there was no statistically significant difference regarding operative time compared THD with SH (OR, -2.54; 95% Cl, -6.85, 1.76; Z=1.16; *P*=0.25; **Figure 3B**).

Return to work time: Four trials provided the information about the average hospital stay after hemorrhoidectomy, there was a significant heterogeneity among trials (Tau<sup>2</sup>=0.03,  $\chi^2$ =11.40, df=3, *P*=0.01, I<sup>2</sup>=74%). No statistically significant difference was noted in terms of hospital stay compared THD with SH in the random-effects model (OR, -0.00; 95% CI, -0.21, 0.20; Z=0.04; *P*=0.96, **Figure 3C**).

Hospital stay: Three trials provided the information about the average time of return to work after hemorrhoidectomy, a statistically significant heterogeneity was observed among trials (Tau<sup>2</sup>=3.79,  $\chi^2$ =7.87, df=3, P=0.02, I<sup>2</sup>=75%), therefore we used the random-effects model for analysis. There was no statistically significant difference in the return to work time compared THD with SH (OR, 1.21; 95% CI, -1.35, 3.77; Z=0.92; *P*=0.36; **Figure 3D**).

Reoperation: Three trials reported the date about the reoperation rate after hemorrhoidectomy, a statistically significant heterogeneity was observed among trials ( $\chi^2$ =5.50, df=4, P=0.24, I<sup>2</sup>=27%), therefore we used the fixed-effects model for analysis. No statistically significant difference in the reoperation rate was noted compared THD with SH (OR, 1.81; 95% Cl, 0.93, 3.54; Z=1.74; P=0.08; Figure 3E).

### Publication bias analysis

The summary of risk of bias assessment and funnel plot are presented in **Figures 4**, **5**. Overall, the included studies were of moderate quality with minimal publication bias.

### Discussion

To improve clinical outcomes of treatment for hemorrhoids, several less invasive and effective techniques, such as ligasure, harmonic and laser hemorrhoidoplasty procedure, were developed. However, none has proven clearly superior to the others [17-21]. SH and THD were described as more effective and a less painful alternative to CH [22, 23]. A retrospective study indicated that both SH and THD are safe procedures and have similar effectiveness for treating grade III hemorrhoids [24]. However, THD seems less effective for Grade III hemorrhoids in a long term follow up [25]. Meanwhile, SH was considered as a safe and effective procedure with sustained favorable results for grades II-IV hemorrhoids [7]. Although previous studies indicated that both THD and SH are safe and effective procedures for hemorrhoids, the outcomes in the mid-term and long-term period still inconsistency.

SD Total Mean SD Total Weight IV, Random, 95% CI

15 20.6%

Mean Difference

-0.15 [-1.13, 0.83]

19 Festen     1 Giordano     6 Paul     6 Venturi     al (95% Cl)     erogeneity: Tau <sup>2</sup> =     t for overall effect: 3     eration til     dy or Subgroup     9 Khafagy     1 Giordano	z = 0.97 me	2.5 1.9 0.5 hi² = 3	196 35 288 4.99, di	2 2.8 2.3	2.9 2.5 2.2 0.5 < 0.00		8.8% 16.5% 26.5% 27.6%	1.50 [0.14, 2.86 -0.60 [-1.01, -0.19 0.70 [0.47, 0.93	5] 9] 3]				
6 Paul 6 Venturi al (95% CI) erogeneity: Tau <sup>2</sup> = t for overall effect: : eration tin <u>dy or Subgroup</u> 9 Khafagy	2.2 3 0.68; Cl Z = 0.97 me	1.9 0.5 hi² = 3	196 35 288 4.99, di	2.8 2.3	2.2 0.5	197 35 <b>298</b>	26.5% 27.6% 100.0%	-0.60 [-1.01, -0.19 0.70 [0.47, 0.93	9] 3]		f		
6 Venturi al (95% Cl) erogeneity: Tau <sup>2</sup> = st for overall effect: : eration tin <u>dy or Subgroup</u> 9 Khafagy	3 0.68; Cl Z = 0.97 <b>me</b>	0.5 hi² = 3	35 288 4.99, di	2.3	0.5	35 298	27.6% 100.0%	0.70 [0.47, 0.93	3]				
al (95% CI) erogeneity: Tau <sup>2</sup> = st for overall effect: ; eration tin <u>dy or Subgroup</u> 9 Khafagy	0.68; Cl Z = 0.97 <b>11E</b>	hi² = 3	288 4.99, di			298	100.0%				Ī		
erogeneity: Tau <sup>2</sup> = st for overall effect: : eration tin <u>dy or Subgroup</u> 19 Khafagy	z = 0.97 me		4.99, di		< 0.00			0.43 [-0.43, 1.29	<u>ו</u> ני				
erogeneity: Tau <sup>2</sup> = st for overall effect: : eration tin <u>dy or Subgroup</u> 19 Khafagy	z = 0.97 me		4.99, di		< 0.00			0.40 [-0.40, 1.20	<u>ч</u>				
eration tin dy or Subgroup 9 Khafagy	z = 0.97 me			I – 4 (F	< 0.00								
eration tin <u>dy or Subgroup</u> 9 Khafagy	me	/ (1 –	0.55)			001),	1 09%		-100	-50	0	50	100
dy or Subgroup 9 Khafagy											SH THD		
dy or Subgroup 9 Khafagy													
9 Khafagy		~		-				No. Diffe			D://		
9 Khafagy	Mean	SH	Total		THD SD	Total	Weight	Mean Difference IV, Random, 95%	CI		lean Difference Random, 95%	CI	
	18.17		15		2.57	15	17.3%	0.07 [-1.70, 1.84				01	
	33	2.50	24	33	4.5	28	17.2%	0.00 [-1.94, 1.94			<b>.</b>		
2 Infantino	25.7	7.8	24 84	26.6	4.5 8.4	20 85	16.9%	-0.90 [-3.34, 1.54			4		
3 Verre	31	8.7	63	20.0	5.6	59	16.8%				-		
								4.00 [1.42, 6.58	-		-		
6 Paul	30	14	196	44	16	197		-14.00 [-16.97, -11.03	-		-		
6 Venturi	33	8.5	35	38	8.7	35	15.4%	-5.00 [-9.03, -0.9/	(]				
al (95% CI)			417			419	100.0%	-2.54 [-6.85, 1.76	5]		•		
	27.05; C	;hi² = 9	3.70, d	f = 5 (P	< 0.00	001);	l² = 95%	•	- H				
• •						,,,			-100	-50	*	50	100
			,								SH THD		
turn to wo	rk +	ima											
	INC				тнр			Mean Difference		Ν	lean Difference		
dy or Subaroup	Mean		Total			Tota	l Weigh		CI				
							-				. italiaolii, <u>3576</u>	01	
									-		I		
								•	-		I		
								•	-		I		
6 venturi	2	0.5	35	2.3	0.6	35	22.0%	o -0.30 [-0.56, -0.0	4]		T		
al (95% Cl)			330			332	100.0%	6 -0.00 [-0.21, 0.20	01				
	0.03: Cł	ni² = 1'	1.40. df	= 3 (P -	= 0.010			•	- I				
• •						,,			-100	-50		50	100
											SH THD		
snital star													
Spritar Sta	y	SH		т	HD			Mean Difference		м	lean Difference		
dy or Subaroup	Mean		Total			Γotal	Weight		CI				
							-						
								•	-				
									-				
o venturi	12.5	3.5	35	13.5	3.9	35	37.3%	-1.00 [-2.74, 0.74	-1		T		
al (95% CI)			122			122	100.0%	1.21 [-1.35, 3.77	1		•		
· ,	3.79: C	;hi² = 7		= 2 (P =	= 0.02)				·				I
• •				- (•	0.02)	,.			-100	-50	-	50	100
		- (-	,								SH THD		
onoration													
operation		SН		тн	п			Odde Ratio			Odde Ratio		
dv or Subaroup	Evo		Total			al W	eight						
	L 4 C						-						
)9 Festen			18										
11 Giordano		2	24	0		8		6.33 [0.29, 138.67]		-	_		
		18	196	7	<b>'</b> 19	7 4	8.3%	2.74 [1.12, 6.73]				-	
16 Paul		2	35	4	3	5 2	28.7%	0.47 [0.08, 2.75]					
16 Paul 16 Venturi													
16 Venturi													
16 Venturi tal (95% CI)			288			8 10	00.0%	1.81 [0.93, 3.54]					
16 Venturi tal (95% CI) al events		23		13	3		0.0%	1.81 [0.93, 3.54]	<u> </u>				
16 Venturi tal (95% CI)	,	df = 4	(P = 0.	.24); l²	3		0.0%	1.81 [0.93, 3.54]	L 0.01	0.1		10	100
a et t 0.9266 a et S 0.1106 a et C 0.92	erogeneity: Tau <sup>2</sup> = 2 for overall effect: Z turn to wo dy or Subgroup 9 Khafagy 2 Infantino 6 Paul 8 Venturi al (95% CI) erogeneity: Tau <sup>2</sup> = 0 tor overall effect: Z bpital stay dy or Subgroup 1 Giordano 3 Verre 6 Venturi al (95% CI) erogeneity: Tau <sup>2</sup> = t for overall effect: coperation dy or Subgroup 9 Khafagy	al (95% CI)     progeneity: Tau <sup>2</sup> = 27.05; C     for overall effect: Z = 1.16     turn to work t     dy or Subgroup Mean     9 Khafagy 1.12     2 Infantino 1.36     6 Paul 1.2     al (95% CI)     progeneity: Tau <sup>2</sup> = 0.03; CF     for overall effect: Z = 0.04     spital stay     dy or Subgroup Mean     1 Giordano 6.3     3 Verre 5.5     6 Venturi 12.5     al (95% CI)     progeneity: Tau <sup>2</sup> = 3.79; C     t for overall effect: Z = 0.92     operation     dy or Subgroup Eve     9 Khafagy	Al (95% CI) progeneity: Tau <sup>2</sup> = 27.05; Chi <sup>2</sup> = 9 for overall effect: $Z = 1.16$ (P = 0 turn to work time SH dy or Subgroup Mean SD 9 Khafagy 1.12 0.23 2 Infantino 1.36 0.6 5 Paul 1.2 1.2 5 Venturi 2 0.5 Al (95% CI) progeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 17 1 Giordano 6.3 5 3 Verre 5.5 6 6 Venturi 12.5 3.5 Al (95% CI) progeneity: Tau <sup>2</sup> = 3.79; Chi <sup>2</sup> = 7 t for overall effect: $Z = 0.92$ (P = 0 Spital stay SH dy or Subgroup Mean SD 1 Giordano 6.3 5 3 Verre 5.5 6 6 Venturi 12.5 3.5 Al (95% CI) progeneity: Tau <sup>2</sup> = 3.79; Chi <sup>2</sup> = 7 t for overall effect: $Z = 0.92$ (P = 0 SH dy or Subgroup Events 1 9 Khafagy 1	al (95% Cl)   417     progeneity: Tau <sup>2</sup> = 27.05; Chi <sup>2</sup> = 93.70, di   for overall effect: Z = 1.16 (P = 0.25)     turn to work time   SH     dy or Subgroup   Mean   SD     20 Khafagy   1.12   0.23   15     21 Infantino   1.36   0.6   84     30 Progeneity:   1.2   1.2   196     31 (95% Cl)   330   330     parogeneity:   Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 11.40, df   6 for overall effect: Z = 0.04 (P = 0.96)     Spital stay   SH   4y or Subgroup   Mean   SD   Total     30 Verre   5.5   6   63   5   24   3 Verre   5.5   6   63     40 or Subgroup   Mean   SD   Total   12.5   3.5   35     al (95% Cl)   122   erogeneity: Tau <sup>2</sup> = 3.79; Chi <sup>2</sup> = 7.87, df   for overall effect: Z = 0.92 (P = 0.36)   0     perogeneity: Tau <sup>2</sup> = 3.79; Chi <sup>2</sup> = 7.87, df   for overall effect: Z = 0.92 (P = 0.36)   0   0     perogeneity: Tau <sup>2</sup> = 3.79; Chi <sup>2</sup> = 7.87, df   for overall effect: Z = 0.92 (P = 0.36)   0   0     perogeneity: Tau <sup>2</sup> = 3.79; Chi <sup>2</sup> = 7.87, df	al (95% Cl)   417     progeneity: Tau <sup>2</sup> = 27.05; Chi <sup>2</sup> = 93.70, df = 5 (P     for overall effect: Z = 1.16 (P = 0.25)     turn to work time     SH     dy or Subgroup   Mean     9 Khafagy   1.12     1.12   0.23   15     9 Khafagy   1.12   0.23   15     1.12   0.23   15   1.12     2 Infantino   1.36   0.6   84   1.14     5 Paul   1.2   1.2   196   1.2     6 Venturi   2   0.5   35   2.3     al (95% Cl)   330   and   and     perogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 11.40, df = 3 (P =   for overall effect: Z = 0.04 (P = 0.96)   Spital stay     Spital stay   SH   T   T     dy or Subgroup   Mean   SD   Total Mean     1 Giordano   6.3   5   24   3.2     3 Verre   5.5   6   63   3.5     6 Venturi   12.5   3.5   35   13.5     al (95% Cl)   122   erogeneity: Tau <sup>2</sup> = 3.79; Chi <sup>2</sup> = 7.87, df =	al (95% CI)   417     progeneity: Tau <sup>2</sup> = 27.05; Chi <sup>2</sup> = 93.70, df = 5 (P < 0.00	Al (95% Cl)   417   419     progeneity: Tau <sup>2</sup> = 27.05; Chi <sup>2</sup> = 93.70, df = 5 (P < 0.00001);	Al (95% Cl)   417   419   100.0%     progeneity: Tau <sup>2</sup> = 27.05; Chi <sup>2</sup> = 93.70, df = 5 (P < 0.00001); l <sup>2</sup> = 95%   for overall effect: Z = 1.16 (P = 0.25)     turn to work time   SH   THD     dy or Subgroup   Mean   SD   Total   Mean   SD   Total   Weight     9   Khafagy   1.12   0.23   15   1.12   0.28   15   26.89     2   Infantino   1.36   0.6   84   1.14   0.5   85   27.99     6   Paul   1.2   1.2   196   1.2   1.2   197   23.39     6   Venturi   2   0.5   35   2.3   0.6   35   22.09     al (95% Cl)   330   332   100.09   argeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 11.40, df = 3 (P = 0.010); l <sup>2</sup> = 74%   for overall effect: Z = 0.04 (P = 0.96)     Spital stay     H   THD     dy or Subgroup Mean SD Total Mean SD Total Weight     1   Giordano   6.3   5   7   59   32.9%     SU Total Mean SD Total Mean SD Total Weight <td>Al (95% Cl)   417   419   100.0%   -2.54 [-6.85, 1.76]     progeneity: Tau<sup>2</sup> = 27.05; Chi<sup>2</sup> = 93.70, df = 5 (P &lt; 0.00001); I<sup>2</sup> = 95%   -2.54 [-6.85, 1.76]     if or overall effect: Z = 1.16 (P = 0.25)   Mean Difference     turn to work time   SH   THD   Mean Difference     dy or Subgroup   Mean   SD   Total   Weight   IV. Random. 95%     9   Khafagy   1.12   0.23   15   1.12   0.28   15   26.8%   0.00 [-0.18, 0.1]     2   Infantino   1.36   0.6   84   1.14   0.5   85   27.9%   0.22 [0.05, 0.3]     5   Paul   1.2   1.2   196   1.2   1.2   197   23.3%   0.00 [-0.24, 0.2]     6   Venturi   2   0.5   35   2.3   0.6   35   22.0%   -0.30 [-0.56, -0.0]     al (95% Cl)   330   332   100.0%   -0.00 [-0.21, 0.2]   erogeneity: Tau<sup>2</sup> = 0.03; Chi<sup>2</sup> = 11.40, df = 3 (P = 0.010); I<sup>2</sup> = 74%   100 [-0.21, 0.2]   erogeneity: Tau<sup>2</sup> = 0.04 (P = 0.96)     Spital stay   SH   THD   Mean Difference   Mean Difference</td> <td>Al (95% Cl) 417 419 100.0% progeneity: Tau<sup>2</sup> = 27.05; Chi<sup>2</sup> = 93.70, df = 5 (P &lt; 0.00001); I<sup>2</sup> = 95% for overall effect: Z = 1.16 (P = 0.25) turn to work time SH THD Mean Difference dy or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% Cl 9 Khafagy 1.12 0.23 15 1.12 0.28 15 26.8% 0.00 [-0.18, 0.18] 2 Infantino 1.36 0.6 84 1.14 0.5 85 27.9% 0.22 [0.05, 0.39] 6 Paul 1.2 1.2 196 1.2 1.2 197 23.3% 0.00 [-0.24, 0.24] 8 Venturi 2 0.5 35 2.3 0.6 35 22.0% -0.30 [-0.56, -0.04] al (95% Cl) 330 332 100.0% -0.00 [-0.21, 0.20] erogeneity: Tau<sup>2</sup> = 0.03; Chi<sup>2</sup> = 11.40, df = 3 (P = 0.010); I<sup>2</sup> = 74% 1 Giordano 6.3 5 24 3.2 5 28 29.8% 3.10 [0.37, 5.83] 3 Verre 5.5 6 63 3.5 7 59 32.9% 2.00 [-0.32, 4.32] 6 Venturi 12.5 3.5 35 13.5 3.9 35 37.3% -1.00 [-2.74, 0.74] al (95% Cl) 122 122 100.0% 1.21 [-1.35, 3.77] erogeneity: Tau<sup>2</sup> = 3.79; Chi<sup>2</sup> = 7.87, df = 2 (P = 0.02); I<sup>2</sup> = 75% to roverall effect: Z = 0.92 (P = 0.36) Coperation SP tal Stay Chi Coverall effect: Z = 0.92 (P = 0.36) Coverall effect: Z = 0.92 (P = 0.36) Coveral effect: Z = 0.92 (</td> <td>Al (95% CI) 417 419 100.0% progeneity: Tau<sup>2</sup> = 27.05; Chi<sup>2</sup> = 93.70, df = 5 (P &lt; 0.00001); l<sup>2</sup> = 95% for overall effect: Z = 1.16 (P = 0.25) turn to work time SH THD Mean Difference M Av or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% CI IV 9 Khafagy 1.12 0.23 15 1.12 0.28 15 26.8% 0.00 [-0.18, 0.18] 2 Infantino 1.36 0.6 84 1.14 0.5 85 27.9% 0.22 [0.05, 0.39] 6 Paul 1.2 1.2 196 1.2 1.2 197 23.3% 0.00 [-0.24, 0.24] 8 Venturi 2 0.5 35 2.3 0.6 35 22.0% -0.30 [-0.56, -0.04] Al (95% CI) 330 332 100.0% -0.00 [-0.21, 0.20] Progeneity: Tau<sup>2</sup> = 0.03; Chi<sup>2</sup> = 11.40, df = 3 (P = 0.010); l<sup>2</sup> = 74% 1 Giordano 6.3 5 24 3.2 5 28 29.8% 3.10 [0.37, 5.83] 3 Verre 5.5 6 63 3.5 7 59 32.9% 2.00 [-0.32, 4.32] 6 Venturi 12.5 3.5 35 13.5 3.9 35 37.3% -1.00 [-2.74, 0.74] al (95% CI) 122 122 100.0% 1.21 [-1.35, 3.77] al (95% CI) 122 122 100.0% 1.21 [-1.35, 3.77] brogeneity: Tau<sup>2</sup> = 3.79; Chi<sup>2</sup> = 7.87, df = 2 (P = 0.02); l<sup>2</sup> = 75% to ro verall effect: Z = 0.92 (P = 0.36) Coperation SH THD Odds Ratio dy or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI M-H 9 Khafagy 1 15 0 15 3.5% 3.21 [0.12, 85.20]</td> <td><math display="block">\begin{array}{c c c c c c c c c c c c c c c c c c c </math></td> <td><math display="block">\begin{array}{c c c c c c c c c c c c c c c c c c c </math></td>	Al (95% Cl)   417   419   100.0%   -2.54 [-6.85, 1.76]     progeneity: Tau <sup>2</sup> = 27.05; Chi <sup>2</sup> = 93.70, df = 5 (P < 0.00001); I <sup>2</sup> = 95%   -2.54 [-6.85, 1.76]     if or overall effect: Z = 1.16 (P = 0.25)   Mean Difference     turn to work time   SH   THD   Mean Difference     dy or Subgroup   Mean   SD   Total   Weight   IV. Random. 95%     9   Khafagy   1.12   0.23   15   1.12   0.28   15   26.8%   0.00 [-0.18, 0.1]     2   Infantino   1.36   0.6   84   1.14   0.5   85   27.9%   0.22 [0.05, 0.3]     5   Paul   1.2   1.2   196   1.2   1.2   197   23.3%   0.00 [-0.24, 0.2]     6   Venturi   2   0.5   35   2.3   0.6   35   22.0%   -0.30 [-0.56, -0.0]     al (95% Cl)   330   332   100.0%   -0.00 [-0.21, 0.2]   erogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 11.40, df = 3 (P = 0.010); I <sup>2</sup> = 74%   100 [-0.21, 0.2]   erogeneity: Tau <sup>2</sup> = 0.04 (P = 0.96)     Spital stay   SH   THD   Mean Difference   Mean Difference	Al (95% Cl) 417 419 100.0% progeneity: Tau <sup>2</sup> = 27.05; Chi <sup>2</sup> = 93.70, df = 5 (P < 0.00001); I <sup>2</sup> = 95% for overall effect: Z = 1.16 (P = 0.25) turn to work time SH THD Mean Difference dy or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% Cl 9 Khafagy 1.12 0.23 15 1.12 0.28 15 26.8% 0.00 [-0.18, 0.18] 2 Infantino 1.36 0.6 84 1.14 0.5 85 27.9% 0.22 [0.05, 0.39] 6 Paul 1.2 1.2 196 1.2 1.2 197 23.3% 0.00 [-0.24, 0.24] 8 Venturi 2 0.5 35 2.3 0.6 35 22.0% -0.30 [-0.56, -0.04] al (95% Cl) 330 332 100.0% -0.00 [-0.21, 0.20] erogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 11.40, df = 3 (P = 0.010); I <sup>2</sup> = 74% 1 Giordano 6.3 5 24 3.2 5 28 29.8% 3.10 [0.37, 5.83] 3 Verre 5.5 6 63 3.5 7 59 32.9% 2.00 [-0.32, 4.32] 6 Venturi 12.5 3.5 35 13.5 3.9 35 37.3% -1.00 [-2.74, 0.74] al (95% Cl) 122 122 100.0% 1.21 [-1.35, 3.77] erogeneity: Tau <sup>2</sup> = 3.79; Chi <sup>2</sup> = 7.87, df = 2 (P = 0.02); I <sup>2</sup> = 75% to roverall effect: Z = 0.92 (P = 0.36) Coperation SP tal Stay Chi Coverall effect: Z = 0.92 (P = 0.36) Coverall effect: Z = 0.92 (P = 0.36) Coveral effect: Z = 0.92 (	Al (95% CI) 417 419 100.0% progeneity: Tau <sup>2</sup> = 27.05; Chi <sup>2</sup> = 93.70, df = 5 (P < 0.00001); l <sup>2</sup> = 95% for overall effect: Z = 1.16 (P = 0.25) turn to work time SH THD Mean Difference M Av or Subgroup Mean SD Total Mean SD Total Weight IV. Random, 95% CI IV 9 Khafagy 1.12 0.23 15 1.12 0.28 15 26.8% 0.00 [-0.18, 0.18] 2 Infantino 1.36 0.6 84 1.14 0.5 85 27.9% 0.22 [0.05, 0.39] 6 Paul 1.2 1.2 196 1.2 1.2 197 23.3% 0.00 [-0.24, 0.24] 8 Venturi 2 0.5 35 2.3 0.6 35 22.0% -0.30 [-0.56, -0.04] Al (95% CI) 330 332 100.0% -0.00 [-0.21, 0.20] Progeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 11.40, df = 3 (P = 0.010); l <sup>2</sup> = 74% 1 Giordano 6.3 5 24 3.2 5 28 29.8% 3.10 [0.37, 5.83] 3 Verre 5.5 6 63 3.5 7 59 32.9% 2.00 [-0.32, 4.32] 6 Venturi 12.5 3.5 35 13.5 3.9 35 37.3% -1.00 [-2.74, 0.74] al (95% CI) 122 122 100.0% 1.21 [-1.35, 3.77] al (95% CI) 122 122 100.0% 1.21 [-1.35, 3.77] brogeneity: Tau <sup>2</sup> = 3.79; Chi <sup>2</sup> = 7.87, df = 2 (P = 0.02); l <sup>2</sup> = 75% to ro verall effect: Z = 0.92 (P = 0.36) Coperation SH THD Odds Ratio dy or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI M-H 9 Khafagy 1 15 0 15 3.5% 3.21 [0.12, 85.20]	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

#### A Early postoperative pain scores SH THD Mean

2.75 1.21

15

2.9 1.5

Study or Subgroup

2009 Khafagy

Figure 3. Surgical parameters: (A) Early postoperative pain scores; (B) Operation time; (C) Return to work time; (D) Hospital stay; (E) Reoperation.

In this meta-analysis, we found that both THD and SH are safe and effective procedures for hemorrhoids. No significantly different was noted in terms of postoperative outcomes

including total complications, bleeding, residual prolapse, urinary retention rate and satisfaction rate. The total recurrent rate was higher in THD compared with SH in the short term follow

Mean Difference

IV, Random, 95% CI



Figure 4. Summary of risk of bias assessment.

up, however, the mid-term outcomes suggested that the recurrent rate was equal in both THD and SH group. These results indicated that the researches focus on the recurrent rate compared SH with THD in a long term follow up are needed in the future.

Postoperative pain is well accepted as a serious problem by patients undergoing hemorrhoidectomy. In this study, we only analyzed the pain scores 24 hours after operations. The present study showed that there was no significantly difference in terms of postoperative pain scores compared THD with SH. While the two techniques were not statistically significantly different regarding operative time, hospital time and return to work time. No statistically significant differences were observed regarding the reoperation rates compared SH with THD.

Cost-effectiveness is an important factor for the surgeons and patients when deciding which

technique to use [26]. Due to the exchange rate and different health polices, medical fee was non-uniform in different countries, and therefore, we could not include them in this metaanalysis. Lehur et al. indicated that a significant difference was noted compared THD with Doppler guidance with SH as regards the cost [15]. A longer operative time and hospital stay time in the THD group may explain this result [12, 16]. However, Venturi et al. reported that THD without Doppler guidance was associated with less cost than SH. Satisfaction rate is another important factor for decision making [16]. Only two studies reported the satisfaction of the patients and there was no significant difference between THD and SH. Base on the above results, SH and THD are equal techniques in the treatment of the hemorrhoids. thus, the present study calls into question the cost-effectiveness and satisfaction rate of THD versus SH in different countries for the surgeons and patients when deciding which technique to use [27].

Our study was in line with previous two studies. A meta-analysis was published in 2012, and only three RCTs encompassing 150 patients were included and one of the trials was published as abstract [28]. THD was associated with significantly less postoperative pain compared to SH. In 2015, a network meta-analysis demonstrated that THD was a safe and quick recover surgical option for the treatment of hemorrhoids with a low complication rate, less postoperative pain and shorter operating time compared with SH [29]. In our study, we reported a latest and more solid evidence results for THD versus SH. Although the recurrence rate of THD was higher in the short term follow up, the recurrence rate was similar in the mid-term follow up between THD and SH. These results suggested that both THD and SH are safe treatments for hemorrhoids with acceptable complication rates and good short-term and midterm outcomes. Never the less, our results also suggested that cost and satisfaction rate may be the initial consideration for surgeon and patients when choosing THD or SH and this result was similar with the previous studies.

There are a number of limitations with the study. First, patients with different grade of hemorrhoids were involved in the including studies which implied that the quantitative



Figure 5. Funnel plot evaluating publication bias. Diagonal lines indicate 95% Cl. Trials within these boundaries indicate minimal publication bias.

analysis was not very powerful and patients selection bias may exist. Second, the statistical heterogeneity was high in terms of operative time, hospital stay and return to work time during operation because of the different outcome measures and treatment considered. Surgical protocol, postoperative care regiment and the methods of outcome measures were various in included studies. Third, these trials only reported the short-term and mid-term outcomes of the THD versus SH. Standardized outcome measures, especially for recurrence with a long term follow up are required. Fourth, although our meta-analysis demonstrated that there was no significantly difference between SH and THD in postoperative pain scores 24 hours after operations. The quantity of analgesia used by patients varied which may influence the results of the pain scores. Fifth, they should also investigate whether different surgical approaches should be used for single versus circumferential. Finally, all the published RCTs are from west countries, studies in the other races may need for further research.

In conclusion, THD and SH are safe and effective method for hemorrhoids in the short-term and mid-term period. Large volume multicenter trials are required to elucidate and confirm these results in long term periods.

### Acknowledgements

Our study was funded by Guangdong province medical science and technology research fund project (grant number: A2017273).

### **Disclosure of conflict of interest**

### None.

Address correspondence to: Qi Yao, Department of Colonproctology Surgery, Shenzhen People's Hospital, No 1017 Dongmen North Road, Luohu District, Shenzhen 518020, Guangdong, China. Tel: 0086-755-22948470; Fax: 0086-755-2553-3497; E-mail: yaoqi19832002@ 163.com; Honglei Chen, Department of Gastrointestinal Endoscopy, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital of Sun Yat-sen University, No 26, Yuancun Er Heng Road, Tianhe

District, Guangzhou 510655, Guangdong, China. Tel: 0086-20-38254092; Fax: 0086-20-38254116; E-mail: chl\_830830@163.com

### References

- [1] Kline RP. Operative management of internal hemorrhoids. JAAPA 2015; 28: 27-31.
- [2] Moult HP, Aubert M and De Parades V. Classical treatment of hemorrhoids. J Visc Surg 2015; 152 Suppl: S3-9.
- [3] Meurette G and Lehur PA. The future of hemorrhoidal surgery: towards an "a la carte" choice of minimally invasive techniques? J Visc Surg 2014; 151: 255-256.
- [4] Morinaga K, Hasuda K and Ikeda T. A novel therapy for internal hemorrhoids: ligation of the hemorrhoidal artery with a newly devised instrument (Moricorn) in conjunction with a Doppler flowmeter. Am J Gastroenterol 1995; 90: 610-613.
- [5] Rubbini M and Tartari V. Doppler-guided hemorrhoidal artery ligation with hemorrhoidopexy: source and prevention of postoperative pain. Int J Colorectal Dis 2015; 30: 625-30.
- [6] Longo A. Stapled anopexy and stapled hemorrhoidectomy: two opposite concepts and procedures. Dis Colon Rectum 2002; 45: 571-572.
- [7] Avgoustou C, Belegris C, Papazoglou A, Kotsalis G and Penlidis P. Evaluation of stapled hemorrhoidopexy for hemorrhoidal disease: 14-year experience from 800 cases. Minerva Chir 2014; 69: 155-166.
- [8] Denoya P, Tam J and Bergamaschi R. Hemorrhoidal dearterialization with mucopexy versus hemorrhoidectomy: 3-year follow-up assessment of a randomized controlled trial. Tech Coloproctol 2014; 18: 1081-1085.

- [9] Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ and McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
- [10] Festen S, van Hoogstraten MJ, van Geloven AA and Gerhards MF. Treatment of grade III and IV haemorrhoidal disease with PPH or THD. A randomized trial on postoperative complications and short-term results. Int J Colorectal Dis 2009; 24: 1401-1405.
- [11] Khafagy W, El Nakeeb A, Fouda E, Omar W, Elhak NG, Farid M and Elshobaky M. Conventional haemorrhoidectomy, stapled haemorrhoidectomy, doppler guided haemorrhoidectomy artery ligation; post operative pain and anorectal manometric assessment. Hepatogastroenterology 2009; 56: 1010-1015.
- [12] Giordano P, Nastro P, Davies A and Gravante G. Prospective evaluation of stapled haemorrhoidopexy versus transanal haemorrhoidal dearterialisation for stage II and III haemorrhoids: three-year outcomes. Tech Coloproctol 2011; 15: 67-73.
- [13] Infantino A, Altomare DF, Bottini C, Bonanno M, Mancini S; THD group of the SICCR (Italian Society of Colorectal Surgery), Yalti T, Giamundo P, Hoch J, El Gaddal A, Pagano C. Prospective randomized multicentre study comparing stapler haemorrhoidopexy with Doppler-guided transanal haemorrhoid dearterialization for third-degree haemorrhoids. Colorectal Dis 2012; 14: 205-211.
- [14] Verre L, Rossi R, Gaggelli I, Di Bella C, Tirone A and Piccolomini A. PPH versus THD: a comparison of two techniques for III and IV degree haemorrhoids. Personal experience. Minerva Chir 2013; 68: 543-550.
- [15] Lehur PA, Didnee AS, Faucheron JL, Meurette G, Zerbib P, Siproudhis L, Vinson-Bonnet B, Dubois A, Casa C, Hardouin JB, Durand-Zaleski I; LigaLongo Study Group. Cost-effectiveness of new surgical treatments for hemorrhoidal disease: a multicentre randomized controlled trial comparing transanal doppler-guided hemorrhoidal artery ligation with mucopexy and circular stapled hemorrhoidopexy. Ann Surg 2016; 264: 710-716.
- [16] Venturi M, Salamina G and Vergani C. Stapled anopexy versus transanal hemorrhoidal dearterialization for hemorrhoidal disease: a threeyear follow-up from a randomized study. Minerva Chir 2016; 71: 365-371.
- [17] Bilgin Y, Hot S, Barlas IS, Akan A and Eryavuz Y. Short- and long-term results of harmonic scalpel hemorrhoidectomy versus stapler hemorrhoidopexy in treatment of hemorrhoidal disease. Asian J Surg 2015; 38: 214-9.

- [18] Lee KC, Chen HH, Chung KC, Hu WH, Chang CL, Lin SE, Tsai KL and Lu CC. Meta-analysis of randomized controlled trials comparing outcomes for stapled hemorrhoidopexy versus LigaSure hemorrhoidectomy for symptomatic hemorrhoids in adults. Int J Surg 2013; 11: 914-918.
- [19] Xu L, Chen H, Lin G and Ge Q. Ligasure versus ferguson hemorrhoidectomy in the treatment of hemorrhoids: a meta-analysis of randomized control trials. Surg Laparosc Endosc Percutan Tech 2015; 25: 106-110.
- [20] Maloku H, Gashi Z, Lazovic R, Islami H and Juniku-Shkololli A. Laser hemorrhoidoplasty procedure vs open surgical hemorrhoidectomy: a trial comparing 2 treatments for hemorrhoids of third and fourth degree. Acta Inform Med 2014; 22: 365-367.
- [21] Chen HL, Woo XB, Cui J, Chen CQ and Peng JS. Ligasure versus stapled hemorrhoidectomy in the treatment of hemorrhoids: a meta-analysis of randomized control trials. Surg Laparosc Endosc Percutan Tech 2014; 24: 285-289.
- [22] Dal Monte PP. Doppler-guided hemorrhoidal artery ligation. Tech Coloproctol 2006; 10: 262.
- [23] Greenberg R, Karin E, Avital S, Skornick Y and Werbin N. First 100 cases with Doppler-guided hemorrhoidal artery ligation. Dis Colon Rectum 2006; 49: 485-489.
- [24] Avital S, Itah R, Skornick Y and Greenberg R. Outcome of stapled hemorrhoidopexy versus Doppler-guided hemorrhoidal artery ligation for grade III hemorrhoids. Tech Coloproctol 2011; 15: 267-271.
- [25] Avital S, Inbar R, Karin E and Greenberg R. Five-year follow-up of Doppler-guided hemorrhoidal artery ligation. Tech Coloproctol 2012; 16: 61-65.
- [26] Ribaric G, Kofler J and Jayne DG. Stapled hemorrhoidopexy, an innovative surgical procedure for hemorrhoidal prolapse: cost-utility analysis. Croat Med J 2011; 52: 497-504.
- [27] Avital S, Inbar R, Karin E and Greenberg R. Is Doppler ultrasonography essential for hemorrhoidal artery ligation? Tech Coloproctol 2012; 16: 291-294.
- [28] Sajid MS, Parampalli U, Whitehouse P, Sains P, McFall MR and Baig MK. A systematic review comparing transanal haemorrhoidal de-arterialisation to stapled haemorrhoidopexy in the management of haemorrhoidal disease. Tech Coloproctol 2012; 16: 1-8.
- [29] Simillis C, Thoukididou SN, Slesser AA, Rasheed S, Tan E and Tekkis PP. Systematic review and network meta-analysis comparing clinical outcomes and effectiveness of surgical treatments for haemorrhoids. Br J Surg 2015; 102: 1603-1618.